226 related articles for article (PubMed ID: 15972797)
1. Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs.
Grajkowski A; Pedras-Vasconcelos J; Wang V; Ausín C; Hess S; Verthelyi D; Beaucage SL
Nucleic Acids Res; 2005; 33(11):3550-60. PubMed ID: 15972797
[TBL] [Abstract][Full Text] [Related]
2. Design and development of thermolytic DNA oligonucleotide prodrugs.
Grajkowski A; Pedras-Vasconcelos J; Ausín C; Verthelyi D; Beaucage SL
Ann N Y Acad Sci; 2005 Nov; 1058():26-38. PubMed ID: 16394123
[TBL] [Abstract][Full Text] [Related]
3. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates.
Puig M; Grajkowski A; Boczkowska M; Ausín C; Beaucage SL; Verthelyi D
Nucleic Acids Res; 2006; 34(22):6488-95. PubMed ID: 17130156
[TBL] [Abstract][Full Text] [Related]
4. Solid-phase synthesis of thermolytic DNA oligonucleotides functionalized with a single 4-hydroxy-1-butyl or 4-phosphato-/thiophosphato-1-butyl thiophosphate protecting group.
Grajkowski A; Ausín C; Kauffman JS; Snyder J; Hess S; Lloyd JR; Beaucage SL
J Org Chem; 2007 Feb; 72(3):805-15. PubMed ID: 17253799
[TBL] [Abstract][Full Text] [Related]
5. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides.
Kamstrup S; Frimann TH; Barfoed AM
Antiviral Res; 2006 Oct; 72(1):42-8. PubMed ID: 16678920
[TBL] [Abstract][Full Text] [Related]
6. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model.
Kootiratrakarn T; Fujimura T; Sano K; Okuyama R; Aiba S; Tagami H; Terui T
Eur J Immunol; 2005 Nov; 35(11):3277-86. PubMed ID: 16245360
[TBL] [Abstract][Full Text] [Related]
8. Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice.
Prater MR; Johnson VJ; Germolec DR; Luster MI; Holladay SD
Vaccine; 2006 Jan; 24(3):263-71. PubMed ID: 16143434
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
Stacey KJ; Blackwell JM
Infect Immun; 1999 Aug; 67(8):3719-26. PubMed ID: 10417129
[TBL] [Abstract][Full Text] [Related]
11. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
[TBL] [Abstract][Full Text] [Related]
13. Improvement of atopic dermatitis in NC/Nga mice by topical application of CpG phosphodiester-ODN.
Kim YS; Kim Y; Lee KJ; Kwon HJ; Kim DS; Kim TY
Int Arch Allergy Immunol; 2007; 144(4):315-24. PubMed ID: 17671391
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3' sequence modifications.
Zimmermann S; Heeg K; Dalpke A
Vaccine; 2003 Feb; 21(9-10):990-5. PubMed ID: 12547613
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
[TBL] [Abstract][Full Text] [Related]
17. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant effect of synthetic oligodeoxyribonucleotides (CpG-ODN) from the Paracoccidioides brasiliensis gp43 gene on the Th2-Th1 immunomodulation of experimental paracoccidioidomycosis.
Amaral CC; Garcia IP; Fernandes GF; Almeida SR; Camargo ZP; Souza MC
Scand J Immunol; 2005 Oct; 62(4):325-33. PubMed ID: 16253119
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
Wu W; Weigand L; Belkaid Y; Mendez S
Eur J Immunol; 2006 Dec; 36(12):3238-47. PubMed ID: 17109471
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of CpG oligonucleotides and chenopodium album extract reverse IgG2a/IgG1 ratios and increase IFN-gamma and IL-10 productions in a murine model of asthma.
Mousavi T; Salek Moghadam A; Falak R; Tebyanian M
Iran J Allergy Asthma Immunol; 2008 Mar; 7(1):1-6. PubMed ID: 18322305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
